Lung Cancer Clinical Trial
Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer
Summary
This study is designed to evaluate the accuracy of lung cancer biomarkers found in the blood in determining if a lung nodule is cancer or benign. Investigators also plan to use another biomarker found in the tumor tissue to identify participants after lung cancer surgery who have a high risk for recurrent cancer so that they can be offered additional drug treatment that will improve their chances of long-term cure. Finally, investigators plan to use one of the blood-based biomarkers to detect any late cancer recurrence
Eligibility Criteria
Inclusion Criteria:
Potentially-resectable lung nodule 8-40 mm diameter suspected (no preop diagnosis) of being a clinically node-negative lung cancer [clinical stage IA-IB (cT1a-T2aN0), <4cm diameter].
If surgical resection is recommended, patient will undergo surgery at Moffitt Cancer Center.
If a definite tissue diagnosis is obtained and stereotactic body radiotherapy (SBRT) is the recommended treatment instead of surgery, the SBRT will be delivered at Moffitt Cancer Center.
>18 years old, male or female.
ECOG performance status 0-1.
Agree to participate in the follow-up protocol.
Any suspected primary lung cancer cell type (except a suspected typical carcinoid tumor, carcinoma in situ or minimally-invasive carcinoma).
Ability to understand and the willingness to sign a written, informed consent document.
Exclusion Criteria:
Participants who are actively receiving any cancer treatment.
Participants with uncontrolled intercurrent illness.
Prior lung cancer within 5 years.
Current active other major cancer except non-melanoma skin cancer.
Patients with pure ground glass opacities (nodules) or hilar masses.
Suspected typical carcinoid cell type (well-differentiated neuroendocrine carcinoma).
Metastatic nodule (suspected) in the lung from an extrapulmonary cancer.
Patient unable to provide informed consent.
Prisoner or incarcerated individual.
For surgical patients, a R1 or R2 resection.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Tampa Florida, 33612, United States More Info
Principal Investigator
How clear is this clinincal trial information?